Moberg Pharma AB Interim report January - September 2018
STRONG MOMENTUM AND PIPELINE PROGRESSPERIOD (JAN-SEP 2018) · Net revenue SEK 342.0 million (348.9, current portfolio 287.1). Current portfolio growth 16% · EBITDA SEK 70.0 million (62.4) including, and SEK 65.0 million (49.4) excluding, capital gains* · EBITDA margin 20% (18) · EBITDA for commercial operations SEK 86.0 million (75.3) · Operating profit (EBIT) SEK 42.3 million (33.5) · Net profit after tax SEK 8.9 million (1.6) · Diluted earnings per share SEK 0.51 (0.09) · Operating cash flow per share SEK 3,29 (1.40) THIRD QUARTER (JUL-SEP 2018) · Net